On study mortality all cancer patients | Bivariate ESA versus control HCT*ESA | Multivariate ESA versus control HCT*ESA | Multivariate ESA versus control HCT*ESA | Multivariate ESA versus control HCT*ESA | ||||||||
Adjusted for | ‐ | age, sex, Hb, tumor type | age, sex, Hb, tumor type and tumor stage | age, sex, Hb, tumor type and ECOG | ||||||||
Patients included | n = 11036 | n = 10972 | n = 9714 | n = 7686 | ||||||||
HR | 95% CI | P* | HR | 95% CI | P* | HR | 95% CI | P* | HR | 95% CI | P* | |
Hct at baseline | ||||||||||||
< 23.5% | 2.19 | 1.35‐3.55 | 0.0110 | 2.13 | 1.30‐3.48 | 0.0191 | 1.92 | 1.13‐3.24 | 0.1220 | 2.85 | 1.47‐5.53 | 0.0254 |
23.5‐29.4% | 0.96 | 0.78‐1.17 | 0.96 | 0.79‐1.18 | 1.00 | 0.80‐1.24 | 1.00 | 0.80‐1.26 | ||||
29.4‐35.3% | 1.17 | 0.99‐1.39 | 1.15 | 0.97‐1.37 | 1.23 | 1.02‐1.48 | 1.17 | 0.96‐1.42 | ||||
35.3‐41.2% | 1.41 | 1.12‐1.76 | 1.39 | 1.10‐1.74 | 1.37 | 1.08‐1.72 | 1.39 | 1.07‐1.79 | ||||
> 41.2% | 1.12 | 0.73‐1.70 | 1.15 | 0.76‐1.76 | 1.15 | 0.75‐1.75 | 1.15 | 0.71‐1.89 | ||||
Missing | 1.09 | 0.76‐1.55 | ‐ | omitted | ‐ | omitted | ‐ | omitted | ‐ | |||
Overall, unadjusted | 1.18 | 1.06‐1.32 | ‐ | 1.18 | 1.06‐1.32 | ‐ | 1.22 | 1.09‐1.36 | ‐ | 1.20 | 1.06‐1.35 | ‐ |